— MannKind Corporation (NASDAQ: MNKD) reported a third-quarter 2019 loss of $0.05 per share versus a loss of $0.08 per share expected.
— The results were driven by increased total revenues from higher Afrezza commercial demand and from the licensing and research agreements with United Therapeutics.
— Net revenues soared by 227% to $14.6 million versus $15.08 million expected.
— Afrezza net revenue jumped by 46% primarily driven by higher product demand, including the first shipment to Brazil, a more favorable mix of Afrezza cartridges and price.
— Collaborations and services revenue surged to $8.19 million from $82,000 last year, primarily driven by the license agreement with United Therapeutics, which began in the fourth quarter of 2018.
— Research and development (R&D) expense decreased by 23% year-over-year, primarily attributable to a decline in clinical trial spending.
Most Popular
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
Key metrics from Nike’s (NKE) Q2 2025 earnings results
NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net
FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips
Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,
